Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation RM-0256 photoimmunotherapy in refractory solid tumors
jRCT2031260118Phase 1Recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RM-0256 in Nonhematologic neoplasms, sponsored by Rakuten Medical, Inc. Primary endpoints: Dose-limiting toxicities, Adverse events and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
RM-0256
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260118.